Actively Recruiting
Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors
Led by Peking University Shenzhen Hospital · Updated on 2026-03-31
10
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, open label, single arm clinical trial to evaluate the safety and the preliminary efficacy of chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of advanced solid tumors positive for one of the following antigens: ephrin type-A receptor 2 (EphA2), claudin-18 isoform 2 (CLDN18.2) , trophoblast cell surface antigen 2 (Trop2), human epidermal growth factor receptor 2 (HER2), guanylyl cyclase-C (GCC), glypican-3 (GPC3) and carcinoembryonic antigen (CEA).
CONDITIONS
Official Title
Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18-70 years, any gender
- Diagnosed with advanced solid tumors positive for EphA2, Claudin18.2, TROP2, HER2, GCC, GPC-3, or CEA
- Positive antigen expression confirmed by immunohistochemical analysis with intensity 2+
- Failed or intolerant to all standard treatments
- Measurable tumor lesions visible on imaging
- ECOG performance status score of 0 to 2
- Expected survival time longer than 3 months
- Good organ function and bone marrow reserve, including:
- Absolute neutrophil count 1.0 x 10^9/L, platelet count 50 x 10^9/L, hemoglobin 80 g/L, no recent blood transfusions or growth factor treatments within 14 days
- Kidney function with creatinine 1.5 x ULN or creatinine clearance 50 mL/min, urine output 10 mL/h
- Coagulation tests (INR and APTT) 1.5 x ULN, excluding those on therapeutic anticoagulants
- Blood oxygen saturation 90%, negative fecal occult blood test
- Willing to provide informed consent and comply with study visits and procedures
You will not qualify if you...
- Pregnant or breastfeeding women
- Unable to guarantee effective contraception for one year after enrollment
- Brain metastases causing significant psychiatric or neurological symptoms
- Serious heart diseases such as arrhythmia
- Autoimmune diseases
- Active bacterial, fungal, or other infections
- Infectious diseases including HIV, syphilis, tuberculosis, or viral hepatitis
- Currently using medications such as glucocorticoids, thrombolytic agents, or antipsychotics
- Considered unsuitable for the trial by investigators for other reasons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China, 518036
Actively Recruiting
Research Team
C
Chen Junhui, professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here